Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21941873 | 0.82 | L3MBTL1 (0.42) | MAPK7FGFR4CD38ACSS2 | |
| SCHEMBL28851081 | 0.73 | L3MBTL1 (0.48) | MAPK7FGFR4CD38ACSS2HDAC1 | |
| SCHEMBL30125665 | 0.72 | GSK3B (0.45) | MAPK7FGFR4CD38ACSS2GSK3B | |
| SCHEMBL21561704 | 0.71 | CD38 (0.40) | MAPK7FGFR4CD38ACSS2HDAC1 | |
| SCHEMBL24801406 | 0.69 | CCNE1 (0.42) | MAPK7FGFR4CD38 | |
| SCHEMBL21561683 | 0.69 | CD38 (0.39) | MAPK7FGFR4CD38ACSS2 | |
| SCHEMBL20191038 | 0.68 | CD38 (0.38) | MAPK7FGFR4CD38ACSS2HDAC1 | |
| SCHEMBL20205014 | 0.68 | FGFR4 (0.40) | MAPK7FGFR4CD38ACSS2HDAC1 | |
| SCHEMBL21561703 | 0.67 | ALDH1A1 (0.38) | MAPK7FGFR4CD38ACSS2 | |
| SCHEMBL27480425 | 0.66 | MAPK7 (0.35) | MAPK7FGFR4CD38ACSS2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | MAPK7 3890/4885FGFR4 2412/4885CD38 2752/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | MAPK7 3890/4885FGFR4 2412/4885CD38 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.